|The FBXL2 (HGNC:13598) fbxl2 (Catalog #MBS9225481) is a Blocking Peptide and is intended for research purposes only. The product is available for immediate purchase.
The FBXL2 (HGNC:13598) fbxl2 product has the following accession number(s) (GI #145559475) (NCBI Accession #Q9UKC9.3) (Uniprot Accession #Q9UKC9). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Calcium-activated substrate recognition component of the SCF (SKP1-cullin-F-box protein) E3 ubiquitin-protein ligase complex, SCF(FBXL2), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Unlike many F-box proteins, FBXL2 does not seem to target phosphodegron within its substrates but rather calmodulin-binding motifs and is thereby antagonized by calmodulin. This is the case for the cyclins CCND2 and CCND3 which polyubiquitination and subsequent degradation are inhibited by calmodulin. Through CCND2 and CCND3 degradation may induce cell-cycle arrest in G(0). SCF(FBXL2) may also mediate PIK3R2 ubiquitination and proteasomal degradation thereby regulating phosphatidylinositol 3-kinase signaling and indirectly autophagy (PubMed:22323446, PubMed:22020328, PubMed:23604317). PCYT1A monoubiquitination by SCF(FBXL2) and subsequent degradation may regulate synthesis of phosphatidylcholine, which is utilized for formation of membranes and of pulmonary surfactant (By similarity).
Cellular Location: Membrane; Lipid-anchor. Tissue Location: Expressed in brain, heart, kidney, liver, lung, pancreas and placenta. Brain, Intestine, Liver, Lung, Nerve tissues are correlated with this protein. Disease Models, Animal, Inflammation, Necrosis, Urogenital Abnormalities are some of the diseases may be linked to FBXL2 Antibody (C-term) Blocking Peptide.